{"nctId":"NCT02387359","briefTitle":"The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)","startDateStruct":{"date":"2014-12"},"conditions":["Irritable Bowel Syndrome Characterized by Constipation"],"count":1054,"armGroups":[{"label":"3.0 mg plecanatide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Plecanatide"]},{"label":"6.0 mg plecanatide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Plecanatide"]},{"label":"Matching placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Plecanatide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n•Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C\n\nExclusion Criteria:\n\n* Refusal or inability to sign informed consent for the trial\n* Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires\n* BMI \\> 35 or \\< 18\n* Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial\n* Women who are pregnant or lactating\n* Diagnosis of IBS-D or IBS-M\n* Organic or obstructive disease of the small or large intestine\n* Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)\n* Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication\n* Unstable medical illness\n* Bilirubin \\> 3X ULN in the absence of a conjugation defect\n* Any laboratory value \\> 3X ULN unless discussed and approved by the study Medical Monitor","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Overall Responders - ITT Population","description":"An Overall Responder was a patient who was a Weekly Responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least one complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks","description":"An Abdominal Pain Intensity Responder was a patient who had a decrease of 30% from baseline for abdominal pain intensity. Baseline was the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks","description":"A Stool Frequency Responder is defined as a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"169","spread":null},{"groupId":"OG002","value":"157","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Sustained Efficacy Responders","description":"A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Stool Consistency","description":"Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS) Rating 1 to 7. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7:\n\n1. Separate hard lumps, like nuts (hard to pass)\n2. Sausage-shaped but lumpy\n3. Like a sausage but with cracks on its surface\n4. Like a sausage or snake, smooth and soft\n5. Soft blobs with clear-cut edges (passed easily)\n6. Fluffy pieces with ragged edges, a mushy stool\n7. Watery, no solid pieces, entirely liquid","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":"1.012"},{"groupId":"OG001","value":"2.02","spread":"0.918"},{"groupId":"OG002","value":"1.98","spread":"0.913"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"1.357"},{"groupId":"OG001","value":"1.59","spread":"1.592"},{"groupId":"OG002","value":"1.86","spread":"1.593"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Straining","description":"Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.39","spread":"1.991"},{"groupId":"OG001","value":"6.47","spread":"1.828"},{"groupId":"OG002","value":"6.50","spread":"1.822"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","spread":"2.464"},{"groupId":"OG001","value":"-2.69","spread":"2.422"},{"groupId":"OG002","value":"-2.88","spread":"2.464"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CSBM Frequency Rate","description":"Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.440"},{"groupId":"OG001","value":"0.22","spread":"0.465"},{"groupId":"OG002","value":"0.28","spread":"0.527"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"1.904"},{"groupId":"OG001","value":"1.46","spread":"2.565"},{"groupId":"OG002","value":"1.41","spread":"2.586"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a SBM Within 24 Hours After the First Dose","description":"Number of patients with a SBM (spontaneous bowel movement) within 24 hours after the first dose of study drug","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"168","spread":null},{"groupId":"OG002","value":"175","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Abdominal Pain","description":"Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (No) to 10 (Worst Possible). Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.10","spread":"1.793"},{"groupId":"OG001","value":"5.94","spread":"1.704"},{"groupId":"OG002","value":"5.95","spread":"1.760"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.79","spread":"2.196"},{"groupId":"OG001","value":"-2.11","spread":"2.215"},{"groupId":"OG002","value":"-2.46","spread":"2.370"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":354},"commonTop":["Diarrhea","Nasopharyngitis","Urinary tract infection","Nausea"]}}}